HS
GOSS icon

HighVista Strategies’s Gossamer Bio GOSS Stock Holding History

HighVista Strategies’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-96,795
Closed -$210K – 121
2022
Q4 		$210K Hold
96,795
– – 0.12% 102
2022
Q3 		$1.16M Hold
96,795
– – 0.66% 38
2022
Q2 		$810K Buy
96,795
+26,753
+38% +$207K 0.49% 47
2022
Q1 		$608K Buy
+70,042
New +$675K 0.39% 65

Other funds holding GOSS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

HighVista Strategies's GOSS Position: Q1 2023 in Review

HighVista Strategies sold out of Gossamer Bio (GOSS) in Q1 2023, closing a stake of 96,795 shares — an estimated $210K sold.

HighVista Strategies first reported a position in GOSS in Q1 2022 and held it in 4 quarters. The position peaked at $1.16M in Q3 2022. 111 funds tracked by Wall St. Rank hold GOSS as of Q1 2023.

  • HighVista Strategies reported no remaining Gossamer Bio position as of Q1 2023 after selling out during the quarter.
  • HighVista Strategies sold 96,795 Gossamer Bio shares in Q1 2023, an estimated $210K.
  • HighVista Strategies first reported a position in Gossamer Bio in Q1 2022 and held it in 4 quarters.
  • HighVista Strategies's Gossamer Bio position peaked at $1.16M in Q3 2022.
  • 111 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2023.

Based on HighVista Strategies's 13F filing for Q1 2023, filed 15 May 2023.